Start-ups floated faster than usual in 2020, a new analysis finds. For a deeper look at biopharma deal trends, our free report is available to download today.
Discount pricing and poor first day defies the recent trend for floating device makers.
2020 was a bountiful year for medtechs making their public debut, with one group, Inari Medical, more than quadrupling in value.
Whether investor enthusiasm for drug stocks holds up this year is the burning question for IPO followers.
Big events for 2021 include the FDA’s decision on aducanumab and pivotal readouts in diabetes and autoimmunity, while investor enthusiasm will be closely monitored.
A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Venture cash raised by private drug developers dipped slightly after two record-breaking quarters, but the party is far from over.
Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.
Drug developers raised a record $4.5bn in IPOs in the third quarter, and investor support for biopharma shows little sign of waning.